Human Cytomegalovirus DNA among Women with Breast Cancer.

Breast cancer is the most common cause of death among women worldwide. Although there are many known riskfactors in breast cancer development, infectious diseases have appeared as one of the important key to contribute tocarcinogenesis formation. The effects of Human Cytomegalovirus (HCMV) on women with breast cancer has beenrecently studied and reported. To contribute to this research trend, this study was conducted to evaluate the associationbetween HCMV and the women with breast cancer. Objective: This experiment aimed to evaluate HCMV DNA in womenwith breast cancer in Ahvaz city, Iran. Materials and Methods: A total of 37 formalin fixed paraffin embedded tissues ofthe patients with ductal breast carcinoma and 35 paraffin embedded tissues of the patients with fibro adenoma as controlgroup were collected. The deparaffinization of all the samples were carried out and the DNA was extracted. Initially,the PCR test was carried out to detect beta –globulin DNA as an internal control. For those samples positive for beta–globulin DNA, Polymerase Chain reaction (PCR) was used to detect HCMV for the tests and control samples. Results:Among 37 ductal breast carcinoma, 20 (54.04%) cases were proved positive for HCMV DNA by PCR. While amongthe 35 control group (fibroadenoma), 10 (28.57%) cases were positive for HCMV DNA (P >0.028). The prevalences ofHCMV DNA among the age groups 30-39, 40-49 and >50 years were 7 (72.22%), 9 (69.23%), 4 (57.14%), respectively(P=0.066). A high frequency of HCMV DNA was detected in tumor grade III, 13/18 (58.33%) compared with tumorgrade II, 7/19 (36.84%) (p=0.044). A high frequency of 16/24 (66.66%) of HCMV DNA was found in invasive ductalbreast cancer compared with 4/13 (30.76%) HCMV DNA in situ (P<0.028). Conclusion: A high prevalence of 54.05%HCMV was found among the patients with ductal carcinoma. The percentages of the high prevalence of HCMV amongage group (40-49) years, tumors grades, and invasive stage were (69.23%), (58.33%), (66.66%), respectively. Furtherstudy of HCMV in the latency phase in patients with ductal carcinoma would be necessary to extend our knowledge.